Neuroscientific Biopharmaceuticals Ltd has released a press release.
Resignation of CEO
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- Appointment of CEO
- 2023 Annual Report and Appendix 4E
- Positive treatment effect in MS animal study
- R&D Tax Incentive Refund Received
- NSB files new patent
Later from Neuroscientific Biopharmaceuticals
- NSB Receives A$2.2M Research & Development Tax Refund
- Appointment of Executive Director & FDA Pre-Ind Meeting
- 2024 Annual Report & Appendix 4E
- NeuroScientific to Acquire Leading Stem Cell Technology
- Previous StemSmart Studies Demonstrate Clinical Response
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals